Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-19
2011-07-19
Kemmerer, Elizabeth C (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S005300, C514S004800, C530S300000
Reexamination Certificate
active
07981860
ABSTRACT:
The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof for the preparation of a medicament for one or more of: treatment and/or prevention of loss of body weight and body fat, prophylaxis or treatment of cachexia, stimulation of appetite, stimulation of food intake, stimulation of weight gain, or increasing body fat mass, or increasing body lean mass. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to the use of a ghrelin splice variant-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to a number of new ghrelin splice variant-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin splice variant-like compounds.
REFERENCES:
patent: 6291653 (2001-09-01), Sheppard et al.
patent: 6967237 (2005-11-01), Bednarek
patent: 2003/0186844 (2003-10-01), Bednarek
patent: 2005/0059015 (2005-03-01), Mintz
patent: 2007/0037751 (2007-02-01), Lange et al.
patent: 1506786 (2005-02-01), None
patent: 1524274 (2005-04-01), None
patent: WO 2005/014032 (2005-02-01), None
patent: WO2005/026392 (2005-03-01), None
Broglio F et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocinol Metab. 2004; 89(6):3062-3065.
Yan M et al. Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science. Oct. 20, 2000; 290(5491)523-527.
Aaronson, N.K. et al., The European Organization for Research and Treatment of Cancer . . . , J. Natl. Cancer Inst., vol. 85; No. 5, pp. 365-376, Mar. 31, 1993.
Alvarez. R. et al., A Novel Regulatory Pathway of Brown Fat Thermogenesis, J. Biol. Chem., vol. 270, No. 10, Mar. 10, 1995, pp. 5666-5673.
Fogelholm, M. et al., Review Comparison of body composition methods: . . . , Eur. J. Clin. Nutr., vol. 51, pp. 495-503 (1997).
E. Bruera, ABC of palliative care Anorexia, cachexia, and nutrition, Br. Med. J., vol. 315:1219-22, Nov. 8, 1997.
Holst, B. et al., Steric Hindrance Mutagenesis versus Alanine . . . , The Am Society for Pharmacology & Experimental Therapeutics, vol. 53, pp. 166-175 (1998).
Carr, A. et al., Pathogenesis of HIV-1 protease inhibitor-associated . . . , Lancet, vol. 351, Issue 9119, pp. 1881-1883 (1998).
Neufeld, G. et al., Vascular endothelial growth factor (VEGF) and its receptors, FASEB J., vol. 13: p. 9-22, Jan. 1999.
Kojima, M. et al., Ghrelin is a growth-hormone-releasing acylated peptide from stomach, Nature, vol. 402, pp. 656-660, Dec. 9, 1999.
Barber M.D. et al., Cancer Cachexia, Surg. Oncol., vol. 8, pp. 133-141 (1999).
Tschop, M. et al., Ghrelin Induces adiposity in rodents, Letters of Nature, vol. 407 p. 908-913, Oct. 19, 2000.
Bednarek, M.A. et al., Structure-Function Studies on the New Growth Hormone-Releasing Peptide . . . , J. Med. Chem., vol. 43, No. 23, pp. 4370-4376 (2000).
Hosoda, H. et al., Purification and Characterization of Rat des-Gln . . . , J Biol. Chem., vol. 275, No. 29, pp. 21995-22000 (2000).
Kahn, B. B. et al., Obesity and insulin resistance, J. Clin. Invest., vol. 106, No. 4, pp. 473-481, Aug. 2000.
Reitman, M.L. et al., Lipoatrophy Revisited, Trends Endocrinol. Metab., vol. 11, No. 10, pp. 410-416 (2000).
Garg, A., Lipodystrophies, Am. J. Med.,vol. 108, pp. 143-152, Feb. 2000.
Lo, J.C. et al., The Effects of Recombinant Human Growth Hormone . . . , J. Clin. Endocrinol. Metab., vol. 86, No. 8, pp. 3480-3487, Aug. 2001.
Islam-Ali, B. et al., Modulation of adipocyte G-protein expression in cancer . . . , British. J. of Cancer, vol. 85, No. 5, pp. 758-763 (2001).
Wren, A.M. et al., Ghrelin Enhances Appetite and Increases Food Intake in Humans, J. Clin. Endocrinol.& Metab., 86(12):5992-95, Dec. 2001.
Wren, A.M. et al., Ghrelin Causes Hyperphagia and Obesity in Rats, Diabetes, vol. 50, pp. 2540-2547, Nov. 2001.
Tisdale, M.J., Cachexia in Cancer Patients, Nat. Pub. Group, vol. 2, pp. 862-871, Nov. 2002.
Inui, A., Cancer Anorexia-Cachexia Syndrome: Current Issues in . . . , CA Cancer J. Clin. 52:72-91 (2002).
Fearon, K.C. et al., Cancer Cachexia, Int. J. Cardiol. 85:73-81 (2002).
Banks, W.A. et al., Extent and Direction of Ghrelin Transport Across the Blood . . . , J. Pharmacol. Exp. Ther., vol. 302, No. 2, pp. 822-827 (2002).
Lawrence, C.B. et al., PRL-Releasing Peptide Reduces Food intake . . . , Endocrinology 143(2), pp. 360-367 (2002).
Berg, A.H. et al., ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism, Trends Endocrinol. Metab., 13(2):84-89 (2002).
Hanada, T. et al., Anti-cachectic effect of ghrelin in nude mice bearing . . . , Biochem. Biophys. Res. Commun., 301:275-79 (2003).
Pemberton, C. et al., C-terminal pro-ghrelin peptides are present in the human circulation, Biochem. Biophys. Res. Comm., 310:567-73 (2003).
Wisse, B.E. et al., Melanocortin Signaling and Anorexia in Chronic Disease States, Ann. N. Y. Acad. Sci., 994:275-81 (2003).
Enomoto, M. et al., Cardiovascular and hormonal effects of subcutaneous administration of . . . , Clin. Sci. (Lond)., 105:431-35 (2003).
Broglio, F. et al., The Endocrine Response to Ghrelin as a Function of Gender in Humans . . . , J. Clin. Endocrinol. Metab., vol. 88, No. 4, pp. 1537-1542, Apr. 2003.
Neary, N.M. et al., Ghrelin Increases Energy Intake in Cancer Patients with Impaired Appetite . . . , J. Clin. Endocrinol. Metab., 89(6):2832-36, Jun. 2004.
Nagaya, N. et al., Effects of Ghrelin Administration on Left Ventricular Function . . . , Circulation,110:3674-79, Dec. 14, 2004.
De Vriese, C. et al., Ghrelin Degradation by Serum and Tissue Homogenates . . . , Endocrinology, 145(11):4997-5005, Nov. 2004.
Gauna, C. et al., Administration of Acylated Ghrelin Reduces Insulin Sensitivity . . . , J. Clin. Endocrinol. Metab., 89(10):5035-42, Oct. 2004.
Sanders, P.M. et al., Role of Lipid-mobilising factor (LMF) in protecting . . . , Br. J. Cancer, 90(6):1274-78 (2004).
Misra ,A. et al., Clinical Features and Metabolic and Autoimmune Derangements . . . , Medicine (Baltimore), vol. 83, No. 1, pp. 18-34, Jan. 2004.
Hegele, R.A. et al., Unbuckling lipodystrophy from insulin . . . , J. Clin. Invest., vol. 114, No. 2, pp. 163-165, Jul. 2004.
Koutkia, P. et al., Metabolic regulation of growth hormone by free fatty acids . . . , Am. J. Physiol. Endocrinol. Metab., Vo., 286:E296-303, Feb. 2004.
Druce ,M.R. et al., Subcutaneous Administration of Ghrelin Stimulates . . . , Int. J. Obes., pp. 1-4 (2005).
Nagaya, N. et al., Treatment of Cachexia with Ghrelin in Patients with COPD, Chest, vol. 128, No. 3, pp. 1187-1193, Sep. 2005.
Laviano, A. et al., Therapy Insight: Cancer Anorexia-Cachexia Syndrome . . . , Nat. Clin. Pract. Oncol., 2 (3):158-65 (2005).
Kojima, M. et al., Ghrelin: Structure and Function, Physiol. Rev., 85:495-522 (2005).
Zhang, J.V. et al., Obestatin, a Peptide Encoded by the Ghrelin Gene . . . , Science, vol. 310, pp. 996-999, Nov. 11, 2005.
Kitlinska, J et al., Differential Effects of Neuropeptide Y on the Growth and Vascularization . . . , Cancer Res. 65(5):1719-28 (Mar. 1, 2005).
Oral, E.A. et al., Leptin Replacement Therapy Modulates Circulating, . . . J. Clin. Endocrinol. Metab., 91(2):621-28 (2006).
Semple, R.K. et al., PPARy and human metabolic disease, J. Clin. Invest., 116(3):581-89 (Mar. 2006).
Körner, M et al., NPY receptors in human cancer; A review of current knowledge, Peptides, 28:419-25 (2007).
Corresponding PCT/US2007/006189 Search Report.
Ohinata et al., [Trp3, Arg5]-ghrelin(1-5) stimulates gr
Ballard Kimberly A
Kemmerer Elizabeth C
LandOfFree
Use of ghrelin splice variant for treating cachexia and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of ghrelin splice variant for treating cachexia and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ghrelin splice variant for treating cachexia and/or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726056